Hetero Drugs Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hetero Drugs Ltd.
A new cheaper version of antiviral remdesivir has been launched locally by a Indian licensee, while Chinese vaccine developers push forward with broader trials of their candidates.
Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.
- Generic Drugs